

TRUSTED BY MORE THAN

10000+
PATIENTS

800+
ONCOLOGISTS

16+
PUBLICATIONS

10+
COUNTRIES



Manjiri Bakre
CEO of OncoStem

Message from the CEO:

On behalf of the OncoStem family, I extend warm wishes to all!

OncoStem continued its growth and R&D activities as planned in FY 2026. Our partnership with Zydus Life Sciences on CanAssist Breast is growing stronger each year. CanAssist Breast data continues to strengthen and has been presented at key national and international conferences, including ABSICON, ISMPO- Jaipur, SABCS in San Antonio, and ESMO in Berlin. Validation of CanAssist Breast in a second prospective randomized completed trial called IDEAL, with our colleagues in Leiden, The Netherlands, shows that CanAssist Breast can predict 'late' distant recurrences up to 15 years from diagnosis, which is helpful to extend endocrine therapy for select patients. CanAssist Breast is included in the **guidelines** of **ABSI**, **ISMPO** in India, which is a big milestone for CanAssist Breast. This year marks another important milestone in showing the **5-year real-world accuracy of CanAssist Breast**. Our data shows that the patients who planned treatment using CanAssist Breast and have been stratified as **low risk** have an excellent survival of **98% at the end of 5 years after avoiding chemotherapy**. We published **3 articles** in 2025 in international peer-reviewed journals. The reach of CanAssist Breast is increasing not only in India but outside as well. Hence, we are coming up with **CanAssist Breast Test** in the form of a **'kit'** to make it more accessible to patients outside India. Kind words from clinicians in advisories and testimonials from patients continue to come in, which keep us going on this journey.

I extend a heartfelt thanks to each of you for your unwavering belief in us and for contributing to making a meaningful difference in the lives of breast cancer patients with our Made in India prognostic test.

Wishing you continued success and good health.

Regards
Manjiri

“The reach of CanAssist Breast is increasing not only in India but outside as well. Hence, we are coming up with **CanAssist Breast Test** in the form of a **'kit'** to make it more accessible to patients outside India. Kind words from clinicians in advisories and testimonials from patients continue to come in, which keep us going on this journey.



Key Highlights and Milestones of the Year

Scaling CanAssist Breast Through Digital Innovation

Highlighting our ongoing focus on innovation, we have deployed our first digital IHC slide scanner, signaling our entry into digital pathology and reinforcing the foundation for scalable, AI-enabled prognostics such as CanAssist Breast.



Excellence in Cancer Diagnostics and Biomarker Innovation

OncoStem Diagnostics received the 'Excellence in Cancer Diagnostics and Biomarker Innovation' award at the BioSpectrum India Awards 2025, presented by Shri Dr. Jitendra Singh, Honourable Minister of Science & Technology, Government of India.



Research & Publications


OncoStem proudly published its latest work in premier international journals.

1. Prognostication by CanAssist Breast Beyond Clinical Risk Assessment in HR+/HER2- EBC Published!

CanAssist Breast provides additional prognostic information by identifying 'low-risk' and 'high-risk' patients from the 'clinically' high-risk and low-risk groups.

Original Article

CanAssist Breast Provides Additional Insightful Prognostic Information in Retrospective, Pooled Secondary Analysis in Clinically Low/ High-Risk Patients With HR+/HER2- EBC



2. Real World Data of CanAssist Breast Published!

First-ever prospective evidence of the use of the CanAssist Breast test published in Scientific Reports.

scientific reports

Article | [Open access](#) | Published: 19 August 2025

Real-world data of CanAssist Breast- first immunohistochemistry and AI-based prognostic test

[Tejal Deepak Durgekar](#), [Manvi Sunder](#), [Badada Ananthamurthy Savitha](#), [Payal Shrivastava](#), [Rahul Bhagat](#), [Naveen Krishnamoorthy](#), [Deepti K. Shivashimpi](#) & [Manjiri Bakre](#)



3. Will CanAssist Breast decipher the biology of Low-to-Intermediate ER Tumors?

A new study in Therapeutic Advances in Medical Oncology highlights the clinical utility of the CanAssist Breast test in early-stage breast cancer with low-intermediate ER expression (1-20%).

THERAPEUTIC ADVANCES in
Medical Oncology

Original Research


CanAssist Breast-based prognostication in low-intermediate estrogen receptor positive (ER^{1%-20%}) early-stage breast cancer patients helps guide treatment decisions

Ther Adv Med Oncol
2025, Vol. 17, 1-13
DOI: 10.1177/
17588359251342218
© The Author(s), 2025.
Article reuse guidelines:
sagepub.com/journals-permissions

Susmita Ghosh, Tejal Deepak Durgekar, Manvi Sunder, Badada Ananthamurthy Savitha, Payal Shrivastava, Naveen Krishnamoorthy, Deepti K. Shivashimpi and Manjiri M. Bakre



Conferences & Scientific Engagement



ESMO Breast Cancer Congress 2025, Germany

Real-World Concordance with Global Genomic Assays

Dr. Ozge Gumusay presented findings on the concordance of CanAssist Breast with Oncotype DX and MammaPrint in early-stage HR+ breast cancer.

The study demonstrated strong alignment with established genomic assays, reinforcing its global clinical relevance.

ESMO BREAST CANCER
MUNICH GERMANY
14-17 NOV 2025

FPN: 42P

Concordance of CanAssist Breast with Oncotype Dx and MammaPrint in Patients with Early-Stage Hormone Receptor-Positive Breast Cancer
Ozge Gumusay¹, Gul Basaran¹, Taner Korkmaz¹, Selcuk Bilgi¹, Yesim Eraltip¹, Aziz Yazan¹, Tejal Durgekar², Manjiri M. Bakror³
¹MAA Acharya Institute of Health Sciences, ²Acibadem Maslak Hospital, ³Acibadem Altunizade Hospital, ⁴OncoStem

ABSTRACT
Background: CanAssist Breast (CAB) is an immunohistochemistry based prognostic test which assesses expression of five biomarkers (CD44, ABCG2, ABCG1, Ki-Cadherin and Piv-Cadherin) and three clinical parameters including tumor size, grade, and node status to categorize patients as low or high risk for distant recurrence within 5 years of diagnosis using an AI based algorithm. Oncotype DX (ODX) and MammaPrint (MP) tests are prospectively validated genomic prognostic tests which use 21 and 75 genes, respectively. All these prognostic tests are used for early breast cancer patients with hormone receptor (HR) positive, HER2 negative tumors to predict risk of distant recurrence. In this study, we aimed to analyze the concordance of CAB test with ODX and MP.

Background of CAB
Figure 2: Global validation data of CAB based risk stratification in patients treated with chemotherapy and endocrine therapy (A) and patients treated with endocrine therapy alone from CAB validation studies (B).

Methodology of the current study
The retrospective study was approved by Acharya Institute Medical Research Assessment Committee (17/16/2025-2025-00011) and is being conducted adhering to ethical guidelines after obtaining informed consent from all patients.

RESULTS
Figure 3: Risk stratification of ODX (cut-off 25) (A) and CAB (B) in ODX cohort; Risk stratification of ODX (cut-off 10) (C); CAB Risk stratification of ODX intermediate risk category (D) (%).

CONCLUSIONS
This study is the first ever prospective comparison of CanAssist Breast test with established prognostic tests Oncotype DX and MammaPrint.

REFERENCE
1. Sarkar, Chandan Prakash V. et al. "Validation of CanAssist Breast immunohistochemistry gene-based prognostic test: clinical and prognostic pathways." *PLoS ONE* 19, 10 (2024): e0240800.
2. Zhang, A., Gupta, A., Krimmer, M. et al. "Survival outcomes in patients with breast cancer: the randomized TAILOR trial." *Breast Cancer Res* 2023 Apr 14;25(1):40.
3. Gupta, A., Basavaraj, C., Sarkar, V. et al. "A retrospective validation of CanAssist Breast in 2022." *arXiv:2211.1181*.
4. Gupta, Chandan Prakash V. et al. "Validation of CanAssist Breast immunohistochemistry gene-based prognostic test: clinical and prognostic pathways." *PLoS ONE* 19, 10 (2024): e0240800.

BCFICON 2026

Dr. Ashish Jaketiya Presented CanAssist Breast as India's Solution for Prognostication

At BCFICON 2026 (March 7), Dr. Ashish Jaketiya delivered an insightful presentation on "CanAssist Breast - India's solution for prognostication in early breast cancer with global validation."

The session highlighted the growing adoption and clinical relevance of CanAssist Breast, particularly in regional oncology practice.

Cost Impact of CanAssist Breast: Single-Centre Study in Rajasthan

ASCO Breakthrough 2023

ICB CAB (CanAssist Breast)

Impact of cost of Oncotype DX versus CanAssist Breast, in Indian prognostic test, in the management of node-negative early breast cancer in a single centre in India.

CONCLUSIONS
This study is the first ever prospective comparison of CanAssist Breast test with established prognostic tests Oncotype DX and MammaPrint.

Illuminate Oncology Town Hall 3.0, Mumbai

Dr. Manjiri Bakre Showcased the Science Behind CanAssist Breast

At the Illuminate Oncology Town Hall held on February 13, 2026, Dr. Manjiri Bakre presented “Guided by Science, Driven by Purpose: India’s First Innovative Breast Cancer Prognostic Test.”

She shared the scientific foundation and real-world impact of CanAssist Breast with leading oncology professionals.



ABSI Midcon, Indore


Dr. D.G. Vijay Presented Real-World Evidence

At ABSI Midcon (February 28, 2026), Dr. D.G. Vijay presented real-world clinical data on CanAssist Breast, emphasizing its prognostic value and role in improving treatment decisions for HR+ HER2- breast cancer patients.

Cochin Oncology Group (COG) Conference

Dr. Prasant Highlights Clinical Utility in Indian Population

Dr. Prasant presented data on CanAssist Breast, focusing on its performance and prognostic relevance in the Indian patient population with early-stage HR+ breast cancer.





Breast Cancer Symposium, Centre for Human Genetics

CanAssist Breast: India's Solution to Prognostication in HR+/HER2- EBC Patients

Shyamili Goutham, Research Scientist at OncoStem Diagnostics, delivered a presentation titled "CanAssist Breast: India's solution to prognostication in HR+/HER2- early breast cancer patients" at the Breast Cancer Symposium at the Centre for Human Genetics, Bangalore, on Jan 29, 2026.

ASICON Conference 2025

The CanAssist Breast at ASICON (December 19, 2025) brought together leading oncological surgeons for in-depth discussions.


The session generated strong engagement and interest among key opinion leaders, reinforcing clinical confidence in the test.



IASO NATCON 2025

Advancing Personalized Treatment Decisions




Dr. Somashekhar presented on CanAssist Breast (October 17, 2025), highlighting its role in improving prognostic accuracy and guiding personalized treatment strategies in breast cancer.



San Antonio Breast Cancer Symposium 2025 (SABCS)

Global Validation Through Poster Presentations

Dr. Manjiri Bakre and Dr. Tanay Shah Presented Real-World data on CanAssist Breast at the Prestigious SABCS 2025 held from December 11–12, 2025.



MABCON 2025, Chennai

Strong Clinical Engagement and Academic Visibility



At MABCON Chennai, Dr. Krishnakumar Rathnam highlighted the importance of India-validated prognostic tools, reinforcing confidence in CanAssist Breast through an engaging presentation and live survey.



Bangalore Tech Summit 2025

Leadership Voice in India's Biotech Growth

Dr. Manjiri Bakre participated in a panel discussion on "Leading India's Rise in Biotech and Health" on November 19, 2025, highlighting innovation and the role of indigenous diagnostics in transforming healthcare.



ISO-ISMPOCON 2025, Jaipur

Clinical Case Studies and Scientific Presentations At ISO-ISMPOCON (Oct 31 – Nov 2, 2025)

- Dr. Senthil Rajappa presented a CanAssist Breast case study
- Tejal D. Durgekar delivered both poster and oral presentations


The conference emphasized practical applications and scientific advancements in prognostication.



Young Women Breast Cancer & Health International Conference, New Delhi

Focus on Genomic Prognostic Assays

At this international conference (November 16, 2025), Dr. Hemant Malhotra presented on "Genomic Prognostic Assays in Breast Cancer," highlighting the evolving role of assays like CanAssist Breast in clinical decision-making.



In the Media

CanAssist Breast Featured on YourStory: Advancing AI-Driven Breast Cancer Care

In a recent feature on YourStory, Dr. Manjiri Bakre shares the inspiring story behind CanAssist Breast, including what led to its conception, the challenges faced along the way, and the impact it is making today. She reflects on the mission to make cancer treatment decisions more precise and personalized, helping patients avoid unnecessary chemotherapy while giving clinicians greater confidence in their choices.



Dr. Manjiri Bakre Shares her thoughts on Empowering Oncologists with Indian Data: Advancing Personalized, Value-Based Cancer Care

A recent article in Express Healthcare highlights a critical shift in oncology, leveraging India-specific data to drive more accurate, personalized, and value-based cancer care. Authored by Dr. Manjiri Bakre, the piece underscores the limitations of relying solely on Western datasets and the urgent need to build robust indigenous evidence for better clinical decision-making.

Empowering oncologists with Indian data: key to personalized, value-based cancer care

In this article, Dr Manjiri Bakre, CEO and Founder, OncoStem Diagnostics highlights the urgent need for India-specific cancer data to guide accurate diagnosis and treatment, noting that reliance on Western datasets often fails to reflect how cancer presents and progresses in Indian patients.

By Dr Manjiri Bakre — On Jan 1, 2026

NEWS GUEST BLOGS



158 0

AI-driven diagnostics can spare 70% of early breast cancer patients from chemotherapy

CanAssist-Breast (CAB) uses AI to predict whether a patient's breast cancer is likely to recur by combining tumour biology with traditional clinical features.



Rashmi Mabiyan • ETHealthWorld

Published On Dec 4, 2025 at 04:13 PM IST • Read by 6946 Professionals



New Delhi: AI-driven molecular diagnostics are ushering in a new era of precision oncology, challenging the long-standing "one-size-fits-all" approach to cancer care. **Dr. Manjiri Bakre**, CEO and Founder, OncoStem


The Economic Times' health magazine features CanAssist Breast.

CanAssist Breast was featured in The Economic Times Health Magazine for its role in advancing AI-driven cancer diagnostics. The feature highlights how our solution is helping clinicians make more informed treatment decisions and enabling many early-stage breast cancer patients to safely avoid unnecessary chemotherapy.

Zydu Lifesciences Led Initiatives

Prognostication and Optimum Treatment planning

Based on TNM, Grade, Age, Ki67



Will CanAssist Breast be of any help in this?

Copyright © OncoStem Diagnostics 2026


Zydu launches Pink Connect and Manthan

Pink Connect is a platform that unites oncologists and stakeholders to discuss breast cancer management, share experiences, and align on treatment approaches. Its main goal is to promote awareness and use of prognostication in EBC, especially in HR+, HER2- cases. **The platform highlights CanAssist Breast, a validated prognostic tool relevant to Indian patients, supporting personalized treatment decisions through expert discussions and case studies.** Overall, Pink Connect fosters collaboration, informed decision-making, and better patient outcomes in breast cancer care.



CanAssist Breast Vs Oncotype DX in node-negative patients

Low & High-risk proportions by CAB & Oncotype DX




CanAssist Breast: 83% of cohort as low-risk
Oncotype DX: 90% as low-risk

NPV	Total cohort	Endocrine Therapy alone	Node negative
CAB	93.4%	93.6%	93.8%
ODX	91.8%	90.8%	92.8%


CAB and ODX have 83% concordance in low-risk stratification

Copyright © OncoStem Diagnostics 2026


Concordance between CAB & ODX



83% concordance between CAB and ODX



Manthan is a dedicated platform for one-on-one conversations between oncologists and medical teams, focusing on personalized discussions around CanAssist Breast. It covers clinical evidence, validation, real-world data, and recent advances, helping clinicians stay at the forefront of early breast cancer prognostication. By bridging clinical data and practical use, Manthan supports informed decisions and effective treatment planning for HR-positive, HER2-negative patients. Ultimately, it's about boosting confidence, sharing insights, and improving patient outcomes.



Tier-3 City Meeting, Data presented by Dr. Rohan Khandelwal

A successful scientific meeting was held in the Tier-3 city of Rewari, involving Dr. Rohan Khandelwal along with key gynecologists and general surgeons. The initiative received high praise from Dr. Rohan and the local medical community, who recognized Zydus' dedication to supporting medical education and scientific engagement at the regional level.

Special mention to Mr. Rudrajit, Mr. Navjot, and Mr. Gyaneshwar for effectively engaging Dr. Rohan Khandelwal, for this meeting. Sincere appreciation to Ms. Janvi Parekh, Mr. Mohit Kasera, Mr. Ali, Mr. Ashish Kumar for their ongoing guidance and support.



Life at OncoStem

